AI-Matured Sub-Nanomolar Anti-PCSK9 Antibody with High-Titer Proprietary Cell Line Production
The PCSK9 Antibody Pair represents the output of Sekbio's integrated AI antibody engineering and proprietary CHO cell line platform. PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) promotes lysosomal degradation of hepatic LDL receptors, raising plasma LDL-C. Inhibition of PCSK9 preserves LDLR and reduces cardiovascular risk.
Using AlphaFold2 structural modeling, protein language model (PLM) guided CDR diversification, and ΔΔG-ranked in silico screening, Sekbio engineered a variant antibody with KD <0.5 nM — a >30-fold improvement over the parental antibody. Combined with a proprietary CHO cell line achieving 4.5 g/L fed-batch titer, this antibody is positioned for both therapeutic development and diagnostic assay OEM supply.
Two complementary engineering platforms that simultaneously maximize affinity and manufacturability.
Protein language models (PLM) and ΔΔG binding free energy prediction screen 10⁵–10⁶ in silico variants, identifying top CDR mutations for >30-fold affinity improvement over the parental antibody.
AI-engineered variant achieves KD <0.5 nM — a >30-fold improvement from the parental ~15 nM. Slower koff provides extended target occupancy critical for PCSK9 blockade efficacy.
Sekbio's engineered CHO-derived host optimizes secretion, folding, and stable integration sites. Compatible with fed-batch and perfusion processes for GMP-ready scale-up.
Achieves 4.5 g/L in standard fed-batch at lab scale — a >5-fold improvement over the parental 0.8 g/L. Stable for ≥30 generations without titer decline.
>98% monomer purity by SEC-HPLC, consistent glycan profile, and low aggregation propensity. Favorable biophysical properties support downstream formulation and long-term stability.
Combined AI affinity maturation and proprietary cell line development reduces time from candidate to stable cell line from 12–14 months to 6–7 months — ~50% cycle time reduction.
Performance data from Sekbio AI antibody engineering workflow and proprietary CHO cell line platform.
AlphaFold2 Multimer and IgFold structural modeling were used to define critical epitopes on the PCSK9 catalytic domain and EGF-AB binding interface. Protein language model-guided CDR diversification followed by ΔΔG-ranked in silico screening identified the optimized variant.
| Parameter | Parental Antibody | AI-Engineered Variant | Improvement |
|---|---|---|---|
| Binding Affinity (KD) | ~15 nM | ~0.45 nM | >30-fold |
| Fed-Batch Titer | ~0.8 g/L | 4.5 g/L | >5-fold |
| Monomer Purity | ~95% | >98% | Improved |
| Development Cycle | 12–14 months | 6–7 months | ~50% reduction |
| AI workflow: AlphaFold2 Multimer structure modeling → PLM-guided CDR diversification → ΔΔG-ranked screening → wet-lab validation. | |||
Sekbio's proprietary CHO cell line platform was applied to produce recombinant PCSK9 antigen for antibody validation and assay development. The production run demonstrates high volumetric yield and analytical-grade purity.
| Parameter | Result |
|---|---|
| Expression Volume | 1,000 mL |
| Protein Concentration | 4.48 mg/mL |
| Total Yield | 1,314 mg |
| Purity — SEC-HPLC | 99% |
| Purity — CE-SDS | 91.9% |
| Production at lab scale (1 L fed-batch). Concentration and purity assessed post-purification. | |
The proprietary CHO-derived stable cell line maintains consistent expression titer over extended passaging, confirming suitability for commercial-scale manufacturing.
Anti-PCSK9 antibody and PCSK9 recombinant protein validated for therapeutic, diagnostic, and research applications.
Anti-PCSK9 antibody as therapeutic candidate for hypercholesterolemia and cardiovascular disease. AI-matured affinity and cell line platform support accelerated IND-enabling studies.
Anti-PCSK9 antibody pair for sandwich immunoassay development targeting quantitative serum PCSK9 measurement in clinical cardiovascular risk stratification.
PCSK9 recombinant antigen (99% SEC-HPLC purity, 4.48 mg/mL) available for antibody screening, assay calibration, and research applications.
End-to-end AI-driven antibody optimization service: structure modeling, PLM-guided affinity maturation, and proprietary cell line development. Available for custom targets.
Request the full technical datasheet, antibody specifications, or discuss OEM supply, licensing, and AI engineering services with our team.